Drotrecogin alfa (activated) in severe sepsis: a systematic review and new cost-effectiveness analysis
Activated drotrecogin alfa (human activated protein C, rhAPC), is produced by recombinant DNA technology, and purports to improve clinical outcomes by counteracting the inflammatory and thrombotic consequences...